EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Anti-Amyloid Therapies for Alzheimer’s Disease and the Amyloid Cascade Hypothesis

Ernesto Fedele iD

International Journal of Molecular Sciences · 24.09.2023 · 24 (19) · 14499

DOI: 10.3390/ijms241914499 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 24.09.2023. Verfasst von Ernesto Fedele. Beteiligte Einrichtung: Pharmacology and Toxicology Unit, Department of Pharmacy, School of Medical and Pharmaceutical Sciences, University of Genoa, Viale Cembrano 4, 16148…. Hauptthemen laut MEDLINE: Alzheimer Disease. Die Arbeit wurde bisher 101-mal zitiert (Crossref) und nennt 184 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: The University of Genoa.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Over the past 30 years, the majority of (pre)clinical efforts to find an effective therapy for Alzheimer’s disease (AD) focused on clearing the β-amyloid peptide (Aβ) from the brain since, according to the amyloid cascade hypothesis, the peptide was (and it is still considered by many) the pathogenic determinant of this neurodegenerative disorder. However, as reviewed in this article, results from the numerous clinical trials that have tested anti-Aβ therapies to date indicate that this peptide plays a minor role in the pathogenesis of AD. Indeed, even Aducanumab and Lecanemab, the two antibodies recently approved by the FDA for AD therapy, as well as Donanemab showed limited efficacy on cognitive parameters in phase III clinical trials, despite their capability of markedly lowering Aβ brain load. Furthermore, preclinical evidence demonstrates that Aβ possesses several physiological functions, including memory formation, suggesting that AD may in part be due to a loss of function of this peptide. Finally, it is generally accepted that AD could be the result of many molecular dysfunctions, and therefore, if we keep chasing only Aβ, it means that we cannot see the forest for the trees.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Alzheimer DiseaseHumansAmyloid beta-PeptidesAmyloidAntibodies, Monoclonal, HumanizedBrain

Stichwörter der Autor:innen

Alzheimer’s diseaseAβ antibodiesamyloid cascade hypothesisclinical trials

Substanzen

Amyloid beta-PeptidesAmyloidAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Pharmacology and Toxicology Unit, Department of Pharmacy, School of Medical and Pharmaceutical Sciences, University of Genoa, Viale Cembrano 4, 16148 Genoa, Italy.
  • IRCCS Ospedale Policlinico San Martino, 16132 Genoa, Italy.

ORCID-Profile: Ernesto Fedele

Förderung

  • The University of Genoa

Zitieren

APA

Fedele, E. (2023). Anti-Amyloid Therapies for Alzheimer’s Disease and the Amyloid Cascade Hypothesis. International Journal of Molecular Sciences, 24(19), 14499. https://doi.org/10.3390/ijms241914499

Vancouver

Fedele E. Anti-Amyloid Therapies for Alzheimer’s Disease and the Amyloid Cascade Hypothesis. International Journal of Molecular Sciences. 2023;24(19):14499. doi:10.3390/ijms241914499

BibTeX
@article{Fedele2023,
  author = {Fedele, Ernesto},
  title = {Anti-Amyloid Therapies for Alzheimer’s Disease and the Amyloid Cascade Hypothesis},
  journal = {International Journal of Molecular Sciences},
  year = {2023},
  volume = {24},
  number = {19},
  pages = {14499},
  doi = {10.3390/ijms241914499}
}
Kostenlos starten →